-
Baricitinib
- names:
Baricitinib
- CAS号:
1187594-09-7
MDL Number: - MF(分子式): C16H17N7O2S MW(分子量): 371.42
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM003085-5mg | 5mg | 99.93% | ¥ 2160.00 | ¥ 2160.00 | 2-3天 | ¥ 0.00 | ||
| YZM003085-250mg | 250mg | 95% | ¥ 4850.00 | ¥ 4850.00 | instock1-2days | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 1187594-09-7 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C16H17N7O2S |
| 分子量 Molecular Weight | 371.42 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度25 mg/mL(67.31 mM;Need ultrasonic and warming) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Baricitinib(CAS:1187594-09-7)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Baricitinib (LY3009104; INCB028050) 为选择性,可口服的JAK1和JAK2抑制剂,IC50分别为5.9 nM 和 5.7 nM |
| Introduction | Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailableJAK1andJAK2inhibitor withIC50s of 5.9 nM and 5.7 nM, respectively. |
| Application1 | |
| Application2 | |
| Application3 |
Baricitinib (LY3009104; INCB028050) 为选择性,可口服的JAK1和JAK2抑制剂,IC50分别为5.9 nM 和 5.7 nM。Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailableJAK1andJAK2inhibitor withIC50s of 5.9 nM and 5.7 nM, respectively.
【1】.Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307.
【2】.Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5.
【3】.Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015 Nov;39(11):1607-18.
【2】.Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5.
【3】.Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015 Nov;39(11):1607-18.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


